CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) — Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California.
Details regarding Lifecore’s participation are as follows:
- 43rd Annual J.P. Morgan Healthcare Conference
Details: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetings
Conference Dates: January 13-16, 2025
Location: San Francisco, California
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
CONTACT: Lifecore Biomedical, Inc. Contact Information: Vida Strategic Partners Stephanie Diaz (Investors) 415-675-7401 [email protected] Tim Brons (Media) 415-675-7402 [email protected] Ryan D. Lake (CFO) Lifecore Biomedical 952-368-6244 [email protected]
